Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 37.8259
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 899558538521.0
- FreeCF/Share 10.0576
- PFCF 99.7216
- PE 48.8811
- Debt/Assets 0.3698
- DivYield 0.006
- ROE 1.0226
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
News
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
Published: February 04, 2026 by: CNBC
Sentiment: Positive
Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ahead thanks to its blockbuster medicines.
Read More
Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly and Company defies valuation skeptics, posting 45% revenue growth and 96% EPS growth in 2025, with 2026 guidance projecting $80–83 billion in revenue and $33.5–35 EPS. LLY's manufacturing investments and pipeline strength, especially tirzepatide and retatrutide, position it to outpace Novo Nordisk A/S in the GLP-1/obesity market. NVO faces 2026 revenue and profit declines due to U.S. pricing pressures, patent expiries, and manufacturing disadvantages despite a strong dividend yield.
Read More
In Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk
Published: February 04, 2026 by: Benzinga
Sentiment: Positive
Over the last two days, Novo Nordisk A/S (NYSE: NVO) stock has plunged around 18% after the company issued a softer outlook for fiscal 2026.
Read More
Here's What Key Metrics Tell Us About Lilly (LLY) Q4 Earnings
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Eli Lilly: A Wonderful Company, But A Stock Priced For Perfection
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly is rated SELL due to lofty valuation, despite extraordinary execution and recent market leadership in GLP-1 and obesity drugs. LLY's current $950B market cap implies sustained 25% annual profit compounding for the foreseeable future — an outcome difficult to achieve at this scale in pharma history. Oral GLP-1 developments may expand markets but will intensify competition and accelerate pricing pressures, undermining long-term dominance assumptions.
Read More
Lilly Stock Jumps After Q4 Earnings Beat and Strong 2026 Guidance
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
LLY beats Q4 earnings and sales estimates as Mounjaro and Zepbound surge. Shares jump on stronger-than-expected revenue and EPS outlook for 2026.
Read More
ADP Jobs Lower, Q4 Earnings Reports Up
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
Fresh Q4 earnings reports and private-sector jobs numbers are giving something of a jolt to market indexes.
Read More
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
Published: February 04, 2026 by: The Motley Fool
Sentiment: Positive
Eli Lilly has leading products in the GLP-1 space, with plans to bring pill versions of its weight loss shots to market. Pfizer is playing catch-up in the GLP-1 space, but it has a long history of innovation.
Read More
Eli Lilly Stock Eyes Best Day Since October After Quarterly Beat
Published: February 04, 2026 by: Schaeffers Research
Sentiment: Positive
Eli Lilly And Co ( NYSE:LLY) stock is up 7.7% to trade at $1,080.69 at last glance, after the pharmaceutical name reported a top- and bottom-line beat for the fourth quarter and issued an upbeat forecast for 2026.
Read More
Eli Lilly shares soar after Q4 beat, strong forecast on weight-loss drugs
Published: February 04, 2026 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) shares surged 9.5% in Wednesday morning trading after the drugmaker posted fourth-quarter results that topped Wall Street expectations and issued a robust forecast for 2026, fueled by soaring demand for its weight‑loss treatments. The company reported revenue of $19.29 billion for the fourth quarter, up 43% from a year earlier and well above analysts' estimate of $18.01 billion.
Read More
Eli Lilly Proves Its GLP-1 Dominance Again, Raising My Price Target
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly delivered robust Q4 results, with revenue up 43% YoY and EPS beating consensus by $0.61. LLY's 2026 guidance calls for $80–83B revenue and $33.50–35 non-GAAP EPS, outpacing consensus and supporting a reiterated buy rating. Mounjaro and Zepbound drove $6.3B in incremental quarterly sales, cementing LLY's GLP-1 market dominance.
Read More
Eli Lilly Says Weight Loss Pill On Track for 2Q Launch in US
Published: February 04, 2026 by: Bloomberg Markets and Finance
Sentiment: Positive
Eli Lilly Chief Financial Officer Lucas Montarce says their weight loss pill is on track to launch in the US in the second quarter, pending approval by the Federal Drug Administration. Montarce says they "feel good about the progress.
Read More
Eli Lilly beats earnings, lifts outlook on booming Zepbound and Mounjaro sales
Published: February 04, 2026 by: Invezz
Sentiment: Positive
Eli Lilly reported stronger-than-expected fourth-quarter earnings and issued robust guidance for the coming year, as soaring demand for its GLP-1 drugs reaffirmed its dominance in the global weight-loss drugs market. The US pharmaceutical giant posted net income of $6.64 billion, or $7.39 a share, up from $4.41 billion, or $4.88 a share, a year earlier.
Read More
Eli Lilly Delivers Knockout Blow To Novo For 2025
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly delivered a robust 4Q25 beat, with revenue up 43% YoY and strong EPS growth, driven by its GLP-1 franchise. Lilly's Mounjaro and Zepbound revenues more than doubled, accounting for over 60% of quarterly sales and signaling sustained demand despite pricing pressure. Management guided 2026 revenue to $80–83 billion and non-GAAP EPS to $33.50–$35.00, implying ~25% top-line growth and continued operational leadership.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Read More
Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch
Published: January 30, 2026 by: CNBC
Sentiment: Positive
Eli Lilly CEO Dave Ricks said upcoming Medicare coverage of obesity drugs could be a major catalyst for the launch of the company's closely watched experimental obesity pill, orforglipron. The launch will likely coincide with Medicare starting to cover obesity medicines for the first time later this year under drug pricing deals Lilly and Novo Nordisk struck with President Donald Trump.
Read More
Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push
Published: January 30, 2026 by: Reuters
Sentiment: Positive
Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in an effort to expand U.S. production and bolster medical supply chains.
Read More
Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
Published: January 30, 2026 by: CNBC
Sentiment: Positive
Eli Lilly said it will spend $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, that will help make its next-generation obesity drugs. That includes a closely watched experimental drug called retatrutide, which has shown the highest weight loss of any treatment seen to date in a late-stage trial.
Read More
Unveiling Lilly (LLY) Q4 Outlook: Wall Street Estimates for Key Metrics
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Trump says Eli Lilly to build six US plants
Published: January 29, 2026 by: Reuters
Sentiment: Positive
U.S. President Donald Trump said on Thursday that he has spoken to the head of pharmaceutical company Eli Lilly and that the company plans to build six plants in the country.
Read More
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Eli Lilly partners with Seamless Therapeutics on gene editing treatments for hearing loss
Published: January 28, 2026 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) announced that it has entered a strategic global research collaboration and licensing agreement with Seamless Therapeutics to develop and commercialize programmable recombinase-based treatments for certain hearing loss indications. The collaboration will use Seamless' proprietary recombinase platform, which enables large, precise DNA insertions independent of the cell's natural DNA repair mechanisms.
Read More
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Where Will Eli Lilly Be in 10 Years?
Published: January 27, 2026 by: The Motley Fool
Sentiment: Positive
The pharmaceutical industry has a well-structured cycle. Eli Lilly is currently benefiting from the early stages of the cycle.
Read More
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Neutral
LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.
Read More
FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly wins FDA Breakthrough Therapy status for sofetabart mipitecan in certain patients with platinum-resistant ovarian cancer.
Read More
Eli Lilly: Breakout To New Highs Sends A Clear Warning Shot
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly remains the dominant force in obesity drugs, with strong momentum ahead of its anticipated Q2 oral obesity drug launch. Eli Lilly's oral drug entry is expected to lower barriers for new patients and accelerate global market penetration, especially outside the U.S. Intensifying generics competition and price wars, particularly in China and other ex-U.S. markets, present key risks, but Eli Lilly's diversified pipeline underpins confidence.
Read More
Eli Lilly: Buy Ahead Of Its Earnings Day (Preview)
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly's forward P/E has compressed below 26x FY2027, while consensus earnings estimates for 2027–2030 continue to rise, signaling undervaluation versus growth. The upcoming oral GLP-1 orforglipron offers a massive manufacturing and pricing advantage over peptide-based rivals, positioning Lilly to dominate the mass-market obesity segment globally. Retatrutide's spectacular Phase 3 results, showing nearly 29% weight loss, establish it as the most potent clinical tool for managing obesity and type 2 diabetes.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000